HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ATH434

Also Known As:

5,7-dichloro-2-((ethylamino)methyl)-8-hydroxy-3-methylquinazolin-4(3H)-one; ATH-434; PBT-434

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - Quinazolinones: 124
        ATH434: 4

Experts

1.	Adlard, Paul A: 2 articles (01/2022 - 01/2021)
2.	Barnham, Kevin J: 2 articles (01/2022 - 01/2021)
3.	Cherny, Robert A: 2 articles (01/2022 - 01/2021)
4.	Finkelstein, David I: 2 articles (01/2022 - 01/2021)
5.	Stefanova, Nadia: 2 articles (01/2022 - 11/2021)
6.	Billings, Jessica L: 1 article (01/2022)
7.	Saleh, Eiman: 1 article (01/2022)
8.	Shukla, Jay J: 1 article (01/2022)
9.	Bradbury, Margaret: 1 article (11/2021)
10.	Heras-Garvin, Antonio: 1 article (11/2021)

Related Diseases

1.	Multiple System Atrophy 01/01/2022 - "The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy." 11/01/2021 - "ATH434 Reduces α-Synuclein-Related Neurodegeneration in a Murine Model of Multiple System Atrophy."
2.	Parkinson Disease (Parkinson's Disease) 01/01/2021 - "ATH434 Reverses Colorectal Dysfunction in the A53T Mouse Model of Parkinson's Disease." 01/01/2022 - "We have previously tested the novel compound ATH434 (formally called PBT434) in preclinical models of Parkinson's disease and shown that it is brain-penetrant, reduces iron accumulation and iron-mediated redox activity, provides neuroprotection, inhibits alpha synuclein aggregation and lowers the tissue levels of alpha synuclein. "
3.	Parkinsonian Disorders (Parkinsonism) 10/01/2022 - "ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism."
4.	Intestinal Pseudo-Obstruction (Intestinal Pseudoobstruction) 01/01/2021 - "ATH434 can reverse some of the GI deficits and enteric neuropathy that occur in a mouse model of PD, and thus may have potential clinical benefit in alleviating the GI dysfunctions associated with PD."
5.	Anosmia 10/01/2022 - "5.5 (pre-hyposmia) and 13.5-month-old (pre-motor) mice were dosed with ATH434 (30 mg/kg/day, oral gavage) for 6 weeks. " 10/01/2022 - "ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism." 10/01/2022 - "ATH434 was able to prevent the development of hyposmia in young tau-/- mice, which coincided with a reduction in bulbar iron and copper levels, an increase in synaptophysin, and a reduction in soluble α-synuclein. "

Related Drugs and Biologics

1.	Synucleins
2.	Iron
3.	alpha-Synuclein
4.	Synaptophysin
5.	Copper
6.	8-hydroxyquinazolin-4(3H)-one